{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-019528","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2022-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.958867+00:00","generated_at":"2026-06-26T07:39:31.064508+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius realigns management: Mazur named CEO; Holubiak becomes Exec. Vice Chairman for commercial launch","bullets":["Leonard Mazur appointed CEO and Chairman; Myron Holubiak transitions to Executive Vice Chairman, effective May 1, 2022.","Holubiak to lead commercial team for upcoming I/ONTAK (CTCL) launch and Mino-Lok Phase 3 completion.","CFO Jaime Bartushak adds Chief Business Officer role; Michael McGuire joins as VP, Program Leader for Anti-Infectives.","Holubiak enters amended employment agreement with $450K salary, 50% bonus potential, 18-month initial term.","Company files Form 8-K; press release dated April 13, 2022, details the changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-019528","json":"https://secwatch.observer/filing/0001213900-22-019528.json","markdown":"https://secwatch.observer/filing/0001213900-22-019528.md","text":"https://secwatch.observer/filing/0001213900-22-019528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390022019528/0001213900-22-019528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390022019528/ea158351-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:39:31.064508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"375f2bd0ee","claim":"Jaime Bartushak changed role as Chief Financial Officer and Chief Business Officer at Citius Pharmaceuticals, Inc..","evidence_excerpt":"Chief Financial Officer Jaime Bartushak will assume additional responsibilities as Chief Business Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390022019528/0001213900-22-019528-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assume additional responsibilities as"},{"label":"Role","value":"Chief Financial Officer and Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"3e68a27bca","claim":"Myron Holubiak was appointed as Executive Vice Chairman at Citius Pharmaceuticals, Inc..","evidence_excerpt":"the Board appointed Myron Holubiak, the current Chief Executive Officer, to the newly created position of Executive Vice Chairman","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390022019528/0001213900-22-019528-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice Chairman"}],"fact_type":"executive_change"},{"claim_id":"aec5619d82","claim":"Leonard Mazur was named as Chief Executive Officer and Chairman at Citius Pharmaceuticals, Inc..","evidence_excerpt":"Leonard Mazur, Citius co-founder and Executive Chairman, has been named as Chief Executive Officer and Chairman.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390022019528/0001213900-22-019528-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"named"},{"label":"Role","value":"Chief Executive Officer and Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}